Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q3 2020 · 10-Q
Revenue$62.84M$62.84M+1,533.1% vs Q3 2019 Net Income$7.82M$7.82MN/M vs Q3 2019 EPS Diluted$0.12$0.12N/M vs Q3 2019 Operating Income$8,989,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$56,594,000N/M Margins · derivedOperating margin14.3%+913.2 pt vs Q3 2019
Net margin12.4%+868.5 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 6, 2020 · 37 d after period end